Asia Pacific Cold Sore Treatment Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2021 –2028 |
 Marktgröße (Basisjahr) | USD 116.71 Million |
 Marktgröße (Prognosejahr) | USD 198.29 Million |
 CAGR |
% |
| Wichtige Marktteilnehmer |
Asia-Pacific Cold Sore Treatment Market, By Strain Type (Herpes Simplex Type-1 Virus and Herpes Simplex Type-2 Virus), Therapeutics (Antiviral Agents, Analgesic Agents and Others), Drug Type (Branded and Generic), Dosage Type (Oral, Topical and Others), End User (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others), Country (Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2028
Market Analysis and Insights: Asia-Pacific Cold Sore Treatment Market
Cold sore treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.2% in the forecast period of 2021 to 2028 and is expected to reach USD 198.29 million by 2027 from USD 116.71 million in 2020.
Rising prevalence of Herpes simplex virus (HSV) globally and proliferation in modes of transmission of HSV, growing technological advancement and development are the major drivers which propelled the demand of the market in the forecast period.
Cold sores or oral herpes are small blisters like abrasions that occur due to the infection caused by the Herpes simplex virus (HSV). Cold sores generally occur on the face, around the lips, chin, cheeks, and nostrils. They generally cause pain, itching before they burst. HSV is one of the most common viruses found to affect the global population and it is endemic throughout the world. Up to 90% of people around the world have at least one form of HSV.
Herpes Simplex Virus (HSV) generally infects the pediatric population worldwide, but according to WHO, people aged 30-49 are at higher risk now for catching the virus, and the prevalence of HSV increases with age. HSV has two types: HSV type-1, and HSV type-2. HSV-1 causes cold sores or oral herpes around lips, nostrils, and cheeks. While HSV-2 cause’s genital herpes. HSV can be spread through the direct mode of transmission which includes oral contact inducing infection with oral herpes, from oral to skin surfaces that appear normal and when there are no symptoms present.
The cold sores treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Cold sores treatment Market Scope and Market Size
The cold sore treatment market is categorized into six notable segments which are based on the strain type, therapeutics type, drug type, dosage type, end user and distribution channel.
- On the basis of strain type, the cold sore treatment market is segmented into herpes simplex type-1 virus, and herpes simplex type-2 virus. In 2021, Herpes simplex type-1 virus (HSV), segment is dominating the market due to its rapidly increasing prevalence.
- On the basis of therapeutics type, the cold sore treatment market is segmented into antiviral agents, analgesic agents, and others. In 2021, antiviral segment is expected to dominate the cold sore treatment market due to the increased count of infectious diseases caused by herpes simplex virus and enhanced product pipeline in antiviral agents are predicted to dominate the market.
- On the basis of drug type, the cold sore treatment market is segmented into branded and generics. In 2021, generics is dominating the cold sore treatment market because it’s very less expensive as compared to branded drugs, and due to the economical nature, and increased usage for the treatment of cold sores.
- On the basis of dosage type, the cold sore treatment market is segmented into oral, topical, and others. In 2021, oral segment is expected to dominate the cold sore treatment market because of its ease of absorption and flexibility to accommodate various types of drugs.
- On the basis of end user, the cold sore treatment market is segmented into hospitals, homecare, specialty clinics, and others. In 2021, homecare segment is dominating the market due to the ease in treatment at home and easy availability of drugs.
- On the basis of distribution channel, the cold sore treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, hospital pharmacy is expected to dominate the market due to the rise in access to cold sore medications and surge in number of prescriptions of cold sore medications on a daily basis are predicted to dominate the market.
Cold Sore Treatment Market Country Level Analysis
The cold sores treatment market is analysed and market size information is on basis of strain type, therapeutic uses, drugs type, dosage type, end user, and distribution channel.
The countries covered in the Cold sore treatment market report are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific.
Japan in Asia-Pacific is expected to grow with the fastest CAGR in the forecasted periods as in the Asia-Pacific’s countries demand for cold sore treatment are increasing very rapidly due to rapidly increasing patient population and advancements in technology.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by manufactures is Creating New Opportunities for Players in the Cold Sore Treatment Market
Cold sore treatment market also provides you with detailed market analysis for every country growth in aesthetic industry with Cold sore treatment sales, impact of advancement in the Cold sore treatment and changes in regulatory scenarios with their support for the Cold sore treatment market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Cold sore treatment Market Share Analysis
Cold sore treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Cold sore treatment market.
The major companies providing cold sore treatment are Merix Pharmaceutical Corp., GlaxoSmithKline plc, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceutical Inc., U.S.A. (A subsidiary OF Glenmark Pharmaceuticals Ltd.), Zydus Pharmaceuticals, Inc.(A Subsidiary of Zydus Cadila), Cipla Inc., AiCuris, Ortho dermatologics’ (a division of bausch health Companies Inc.), Foundation Consumer Healthcare, Squarex, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Aurobindo Pharma U.S.A. (A Subsidiary of Aurobindo Pharma), WOCKHARDT, Novartis AG, Jubilant Cadista (a subsidiary of Jubilant Life Sciences Limited), Hikma Pharmaceuticals PLC, Hetero Healthcare Limited, Apotex Inc., Avanir Pharmaceuticals, Inc., HRA Pharma, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the cold sore treatment market.
- In February 2020, Ortho Dermatologics announced the launch of first, non-reimbursed, prescription program in dermatology, telemedicine platform on dermatology.com in the U.S. This will help the patients to consult with physicians, doctors and order branded dermatology products available on the website. This will help the company to expand its business and make the product profile strong.
Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the Cold sore treatment market which also provides the benefit for organisation to improve their offering for Cold sores treatments.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC COLD SORE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET DRUG TYPE COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF COLD SORE INFECTION
6.1.2 PROLIFERATION IN MODES OF TRANSMISSION OF HERPES SIMPLEX VIRUS
6.1.3 INCREASING AWARENESS ABOUT SEXUALLY TRANSMITTED DISEASES
6.1.4 AVAILABILITY OF GENERIC DRUGS
6.1.5 RISING RATE OF HSV INFECTION AMONG WOMEN
6.2 RESTRAINTS
6.2.1 PATENT TERMINATION OF MARKETED DRUGS
6.2.2 RISKS OF OTHER DISEASES ASSOCIATED WITH COLD SORE
6.2.3 DEARTH OF AWARENESS ABOUT THE ONSET AND SYMPTOMS OF COLD SORE TREATMENT
6.3 OPPORTUNITIES
6.3.1 INCREASING DISPOSABLE INCOME
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.3 INCREASING RESEARCH AND DEVELOPMENT
6.3.4 INCREASING USE OF COLD SORE PATCHES
6.4 CHALLENGES
6.4.1 RISE IN ALTERNATIVE TREATMENTS
6.4.2 EMERGENCE OF DRUGS RESISTANT TO ACYCLOVIR
6.4.3 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS USED FOR TREATING COLD SORE
7 COVID-19 IMPACT ON ASIA-PACIFIC COLD SORE TREATMENT MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS
7.5 CONCLUSION
8 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY STRAIN TYPE
8.1 OVERVIEW
8.2 HERPES SIMPLEX TYPE 1 VIRUS
8.3 HERPES SIMPLEX TYPE 2 VIRUS
9 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY THERAPEUTICS
9.1 OVERVIEW
9.2 ANTIVIRAL AGENTS
9.2.1 ACYCLOVIR
9.2.2 FAMCICLOVIR
9.2.3 PENCICLOVIR
9.2.4 VALACYCLOVIR
9.2.5 DOCOSANOL
9.3 ANALGESIC AGENTS
9.3.1 CARMEX
9.3.2 HERPECIN
9.3.3 OTHERS
9.4 OTHERS
10 ASIA-PACIFIC COLD SORETREATMENT MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 GENERICS
10.2.1 OTC
10.3 BRANDED
10.3.1 PRESCRIPTION
10.3.2 OTC
11 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DOSAGE TYPE
11.1 OVERVIEW
11.2 ORAL
11.3 TABLETS
11.4 PILLS
11.5 TOPICAL
11.5.1 CREAM
11.5.2 OINTMENTS
11.5.3 GEL
11.5.4 SPRAY
11.6 OTHERS
12 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOME CARE
12.3 HOSPITALS
12.4 SPECIALTY CLINICS
12.5 OTHERS
13 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITALS PHARMACY
13.3 ONLINE PHARMACY
13.4 RETAIL PHARMACY
14 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY GEOGRAPHY
14.1 ASIA PACIFIC
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 AUSTRALIA
14.1.5 SOUTH KOREA
14.1.6 SINGAPORE
14.1.7 MALAYSIA
14.1.8 PHILIPPINESS
14.1.9 INDONESIA
14.1.10 THAILAND
14.1.11 VIETNAM
14.1.12 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC COLD SORE TREATMENT MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT
17 COMPANY PROFILE
17.1 GLAXOSMITHKLINE PLC
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 ORTHO DERMATOLOGICS’ (A DIVISION OF BAUSCH HEALTH COMPANIES INC.)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 FOUNDATION CONSUMER HEALTHCARE
17.3.1 COMPANY SNAPSHOT
17.3.2 COMPANY SHARE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 NOVARTIS AG
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 AMNEAL PHARMACEUTICALS LLC
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 AICURIS GMBH & CO. KG
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 APOTEX INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 CIPLA LIMITED
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENTS
17.11 GLENMARK PHARMACEUTICALS, INC., USA (A SUBSIDIARY OF GLENMARK PHARMACEUTICAL LTD.)
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 HIKMA PHARMACEUTICALS PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 HRA PHARMA
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 HETERO HEALTHCARE LIMITED
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 JUBILANT CADISTA (A SUBSIDIARY OF JUBILANT LIFE SCIENCES LIMITED)
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 MERIX PHARMACEUTICAL CORP.
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 SQAUREX
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 VIATRIS INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 WOCKHARDT
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Tabellenverzeichnis
LIST OF TABLES
TABLE 1 ASIA-PACIFICCOLD SORE TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 GENERIC DRUGS USED FOR THE TREATMENT OF HSV (COLD SORES)
TABLE 3 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC HERPES SIMPLEX TYPE 1 VIRUS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC HERPES SIMPLEX TYPE 2 VIRUS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY THERAPEUTICS 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC OTHERS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DRUG TYPE 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC GENERICS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DOSAGE TYPE 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC ORAL IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC ORAL SEGMENT IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC TOPICAL SEGMENT IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TOPICAL SEGMENT IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC OTHERS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC HOSPITALS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITALS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC SPECIALTY CLINICS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC OTHERS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC HOSPITALS PHARMACY IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC ONLINE PHARMACY IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC RETAIL PHARMACY IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC COLD SORE MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC COLD SORE MARKET, BY STRAIN, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 38 ASIA PACIFIC GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 41 ASIA PACIFIC ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 44 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 45 CHINA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 46 CHINA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 47 CHINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 48 CHINA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 49 CHINA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 CHINA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 51 CHINA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 52 CHINA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 53 CHINA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 54 CHINA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 55 CHINA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 56 CHINA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 57 JAPAN COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 58 JAPAN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 59 JAPAN ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 60 JAPAN ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 61 JAPAN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 62 JAPAN GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 63 JAPAN BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 64 JAPAN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 65 JAPAN ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 66 JAPAN TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 67 JAPAN COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 68 JAPAN COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 69 INDIA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 70 INDIA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 71 INDIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 72 INDIA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 73 INDIA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 74 INDIA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 75 INDIA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 76 INDIA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 77 INDIA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 78 INDIA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 79 INDIA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 80 INDIA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 81 PERU COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 82 PERU COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 83 AUSTRALIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 84 AUSTRALIA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 85 AUSTRALIA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 86 AUSTRALIA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 87 AUSTRALIA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 88 AUSTRALIA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 89 AUSTRALIA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 90 AUSTRALIA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 91 AUSTRALIA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 92 AUSTRALIA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 93 SOUTH KOREA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 94 SOUTH KOREA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 95 SOUTH KOREA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 96 SOUTH KOREA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 97 SOUTH KOREA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 98 SOUTH KOREA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 99 SOUTH KOREA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 100 SOUTH KOREA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 101 SOUTH KOREA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 102 SOUTH KOREA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 103 SOUTH KOREA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 104 SOUTH KOREA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 105 SINGAPORE COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 106 SINGAPORE COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 107 SINGAPORE ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 108 SINGAPORE ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 109 SINGAPORE COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 110 SINGAPORE GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 111 SINGAPORE BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 112 SINGAPORE COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 113 SINGAPORE ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 114 SINGAPORE TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 115 SINGAPORE COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 116 SINGAPORE COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 117 MALAYSIA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 118 MALAYSIA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 119 MALAYSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 120 MALAYSIA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 121 MALAYSIA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 122 MALAYSIA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 123 MALAYSIA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 124 MALAYSIA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 125 MALAYSIA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 126 MALAYSIA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 127 MALAYSIA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 128 MALAYSIA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 129 PHILIPPINESS COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 130 PHILIPPINESS COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 131 PHILIPPINESS ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 132 PHILIPPINESS ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 133 PHILIPPINESS COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 134 PHILIPPINESS GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 135 PHILIPPINESS BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 136 PHILIPPINESS COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 137 PHILIPPINESS ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 138 PHILIPPINESS TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 139 PHILIPPINESS COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 140 PHILIPPINESS COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 141 INDONESIA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 142 INDONESIA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 143 INDONESIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 144 INDONESIA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 145 INDONESIA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 146 INDONESIA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 147 INDONESIA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 148 INDONESIA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 149 INDONESIA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 150 INDONESIA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 151 INDONESIA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 152 INDONESIA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 153 THAILAND COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 154 THAILAND COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 155 THAILAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 156 THAILAND ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 157 THAILAND COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 158 THAILAND GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 159 THAILAND BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 160 THAILAND COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 161 THAILAND ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 162 THAILAND TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 163 THAILAND COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 164 THAILAND COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 165 VIETNAM COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 166 VIETNAM COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 167 VIETNAM ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 168 VIETNAM ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 169 VIETNAM COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 170 VIETNAM GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 171 VIETNAM BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 172 VIETNAM COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 173 VIETNAM ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 174 VIETNAM TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 175 VIETNAM COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 176 VIETNAM COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 177 REST OF ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
Abbildungsverzeichnis
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC COLD SORE TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC COLD SORE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC COLD SORE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC COLD SORE TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC COLD SORE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC COLD SORE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC COLD SORE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC COLD SORE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC COLD SORE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC COLD SORE TREATMENT MARKET: MARKET DRUG TYPE COVERAGE GRID
FIGURE 11 ASIA-PACIFIC COLD SORE TREATMENT MARKET: SEGMENTATION
FIGURE 12 GROWING PREVALENCE OF COLD SORE TREATMENT WORLDWIDE, AND PROLIFERATION IN MODES OF TRANSMISSION OF HERPES SIMPLEX VIRUS (HSV), AND INCREASING AWARENESS ABOUT SEXUALLY TRANSMITTED DISEASES ARE DRIVING THE ASIA-PACIFIC COLD SORE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 HERPES SIMPLEX TYPE 1 VIRUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC COLD SORE TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC COLD SORE TREATMENT MARKET
FIGURE 15 PREVALENCE OF HERPES SIMPLEX VIRUS TYPE 1, AMONG PERSONS AGED 14-49 YEARS, BY AGE GROUP: IN THE U.S. 2015–2016
FIGURE 16 PREVALENCE OF HERPES SIMPLEX VIRUS TYPE 1, BY RACE AND HISPANIC ORIGIN: U.S. 2015–2016
FIGURE 17 PREVALENCE OF HERPES SIMPLEX VIRUS TYPE 1, BY SEX: IN DIFFERENT COUNTRIES 2015–2016
FIGURE 18 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY STRAIN TYPE, 2020
FIGURE 19 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY STRAIN TYPE, 2020-2028 (USD MILLION)
FIGURE 20 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY STRAIN TYPE, CAGR (2021-2028)
FIGURE 21 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY STRAIN TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY THERAPEUTICS, 2020
FIGURE 23 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY THERAPEUTICS , 2020-2028 (USD MILLION)
FIGURE 24 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY THERAPEUTICS, CAGR (2021-2028)
FIGURE 25 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY THERAPEUTICS, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DRUG TYPE, 2020
FIGURE 27 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DRUG TYPE 2020-2028 (USD MILLION)
FIGURE 28 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 29 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DOSAGE TYPE, 2020
FIGURE 31 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DOSAGE TYPE 2020-2028 (USD MILLION)
FIGURE 32 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DOSAGE TYPE, CAGR (2021-2028)
FIGURE 33 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DOSAGE TYPE, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY END USER, 2020
FIGURE 35 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY END USER 2020-2028 (USD MILLION)
FIGURE 36 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY END USER, CAGR (2021-2028)
FIGURE 37 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 39 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
FIGURE 40 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 41 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 ASIA PACIFIC COLD SORE TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 43 ASIA PACIFIC COLD SORE TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 44 ASIA PACIFIC COLD SORE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 45 ASIA PACIFIC COLD SORE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 ASIA PACIFIC COLD SORE TREATMENT MARKET: BY STRAINS (2021-2028)
FIGURE 47 ASIA-PACIFIC COLD SORE TREATMENT MARKET: COMPANY SHARE 2020 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
